149. Lejeune, P., Cruciani, V., Berg-Larsen, A., Schlicker, A., Mobergslien, A., Bartnitzky, L., Berndt, S., Zitzmann-Kolbe, S., Kamfenkel, C., Stargard, S., et al. (2021). Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. J. Immunother. Cancer 9, e002387. https://doi.org/10.1136/jitc-2021-002387.

150. Wickstroem, K., Hagemann, U.B., Cruciani, V., Wengner, A.M., Kristian, A., Ellingsen, C., Siemeister, G., Bjerke, R.M., Karlsson, J., Ryan, O.B., et al. (2019). Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models. J. Nucl. Med. 60, 1293-1300. https://doi.org/10.2967/jnumed.118.223701.

151. Fujisaka, Y., Kurata, T., Tanaka, K., Kudo, T., Okamoto, K., Tsurutani, J., Kaneda, H., Okamoto, I., Namiki, M., Kitamura, C., and Nakagawa, K. (2015). Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest. New Drugs 33, 380-388. https://doi.org/10.1007/s10637-014-0196-0.

152. Hassan, R., Cohen, S.J., Phillips, M., Pastan, I., Sharon, E., Kelly, R.J., Schweizer, C., Weil, S., and Laheru, D. (2010). Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin. Cancer Res. 16, 6132-6138. https://doi.org/10.1158/1078-0432.CCR-10-2275.

153. Hassan, R., Kindler, H.L., Jahan, T., Bazhenova, L., Reck, M., Thomas, A., Pastan, I., Parno, J., O'Shannessy, D.J., Fatato, P., et al. (2014). Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemtretexed and cisplatin in advanced unresectable pleural mesothelioma. Clin. Cancer Res. 20, 5927-5936. https://doi.org/10.1158/1078-0432.CCR-14-0804.

154. Nicolaides, N.C., Schweizer, C., Somers, E.B., Wang, W., Fernando, S., Ross, E.N., Grasso, L., Hassan, R., and Kline, J.B. (2018). CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. Cancer Biol. Ther. 19, 622-630. https://doi.org/10.1080/15384047.2018.1449614.

155. Hassan, R., Schweizer, C., Lu, K.F., Schuler, B., Remaley, A.T., Weil, S.C., and Pastan, I. (2010). Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 68, 455-459. https://doi.org/10.1016/j.lungcan.2009.07.016.

156. Lindenberg, L., Thomas, A., Adler, S., Mena, E., Kurdziel, K., Maltzman, J., Wallin, B., Hoffman, K., Pastan, I., Paik, C.H., et al. (2015). Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. Oncotarget 6, 4496-4504. https://doi.org/10.18632/oncotarget.2883.

157. Hatterer, E., Chauchet, X., Richard, F., Barba, L., Moine, V., Chatel, L., Broyer, L., Pontini, G., Bautzova, T., Juan, F., et al. (2020). Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. mAbs 12, 1739408. https://doi.org/10.1080/19420862.2020.1739408.

158. Ye, S., Cohen, D., Belmar, N.A., Choi, D., Tan, S.S., Sho, M., Akamatsu, Y., Kim, H., Iyer, R., Cabel, J., et al. (2019). A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity. Cancer Immunol. Res. 7, 1864-1875. https://doi.org/10.1158/2326-6066.CIR-18-0805.

159. Luke, J.J., Barlesi, F., Chung, K., Tolcher, A.W., Kelly, K., Hollebecque, A., Le Tourneau, C., Subbiah, V., Tsai, F., Kao, S., et al. (2021). Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J. Immunother. Cancer 9, e002015. https://doi.org/10.1136/jitc-2020-002015.

160. Molloy, M.E., Austin, R.J., Lemon, B.D., Aaron, W.H., Ganti, V., Jones, A., Jones, S.D., Strobel, K.L., Patnaik, P., Sexton, K., et al. (2021). Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. Clin. Cancer Res. 27, 1452-1462. https://doi.org/10.1158/1078-0432.CCR-20-3392.

161. Boisgard, R., Prothon, J., Torrielli, C., Chames, P., and Kerfelec, B. (2026). Nanobody-enhanced T cell cancer immunotherapy: Advancing precision medicine. Mol. Ther. 34, 678-713. https://doi.org/10.1016/j.ymthe.2025.10.043.

162. Pham, E., Lutterbuese, P., Deegen, P., Mariano, N., Matthes, K., Wahl, J., Bogner, P., Lane, J., Wilson, K.L., Yabut, R., et al. (2023). Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN. Cancer Res. 83, ND06. https://doi.org/10.1158/1538-7445.AM2023-ND06.

163. Smans, K., Nesspor, T., De Breuker, S., Van Heerde, E., Valckx, A., Van Slycken, N., Sproesser, K., Mattson, B., Packman, K., Fisher, J., et al. (2024). 144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting T-cell engaging bispecific antibody for treatment of mesothelin-positive cancers. Eur. J. Cancer 211, 114666. https://doi.org/10.1016/j.ejca.2024.114666.

164. Afacan, N., Piscitelli, C., Zwierzchowski, P., Cao, S., Li, J., Wong, W., White-Moyes, K., Spreter von Kreudenstein, T., and Weisser, N.E., ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid. https://www.zymworks.com/wp-content/uploads/2023/04/ZW171-Poster_AACR-2023.pdf.

165. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. (2014). Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112-120. https://doi.org/10.1158/2326-6066.CIR-13-0170.

166. Beatty, G.L., O'Hara, M.H., Lacey, S.F., Torigian, D.A., Nazimuddin, F., Chen, F., Kulikovskaya, I.M., Soulen, M.C., McGarvey, M., Nelson, A.M., et al. (2018). Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase I Trial. Gastroenterology 155, 29-32. https://doi.org/10.1053/j.gastro.2018.03.029.

167. Adusumilli, P.S., Zauderer, M.G., Rivière, I., Solomon, S.B., Rusch, V.W., O'Cearbhaill, R.E., Zhu, A., Cheema, W., Chintala, N.K., Halton, E., et al. (2021). A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 11, 2748-2763. https://doi.org/10.1158/2159-8290.CD-21-0407.

168. Adusumilli, P.S., Amador, A.M., Chintala, N., Hou, Z., Offin, M., Pineda, J., Senechal, B., Quach, H.T., Bellis, R., Banerjee, S., et al. (2021). 46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor. Ann. Oncol. 32, S1392-S1393. https://doi.org/10.1016/j.annonc.2021.10.063.

169. Fang, J., Sun, Y., Guo, X., Xie, B., Wang, H., Mao, W., Zhu, Z., Liu, Z., Hu, F., Yuan, M., et al. (2020). Safety and efficacy of chimeric antigen receptor T cells modified to target mesothelin and express PD-1 antibodies in patients with relapsed/refractory solid cancers in a phase I trial. J. Clin. Oncol. 38, 3039. https://doi.org/10.1200/JCO.2020.38.15_suppl_3039.

170. Chiorean, E.G., Chapuis, A., Coveler, A., Yeung, C., Gooley, T., Zhen, D.B., King, G., Cohen, S., Hannan, L., Safyan, R., et al. (2024). Abstract A003: Preliminary safety results from a phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T cell receptor (TCR) (FH-TCR TMSLN) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDA). Cancer Res. 84, A003. https://doi.org/10.1158/1538-7445.PANCA2023-A003.

171. McCarthy, D., Lofgren, M., Watt, A., Horton, H., Kieffer-Kwon, P., Ding, J., Kobold, S., Baeuerle, P.A., Hofmeister, R., Gutierrez, D.A., and Tighe, R. (2023). Functional enhancement of mesothelin-targeted TRuc-T cells by a PD1-CD28 chimeric switch receptor. Cancer Immunol. Immunother. 72, 4195-4207. https://doi.org/10.1007/s00262-023-03556-7.

172. Annunziata, C.M., Ghobadi, A., Pennella, E.J., Vanas, J., Powell, C., Pavelova, M., Wagner, C., Kuo, M., Dansky Ullmann, C., Hassan, R., and Thaker, P.H. (2020). Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J. Clin. Oncol. 38, 3014. https://doi.org/10.1200/JCO.2020.38.15_suppl_3014.

173. Li, X., Wang, X., Wang, H., Zuo, D., Xu, J., Feng, Y., Xue, D., Zhang, L., Lin, L., and Zhang, J. (2024). A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy. J. Hematol. Oncol. 17, 116. https://doi.org/10.1186/s13045-024-01635-5.

174. Hassan, R., Butler, M., O'Cearbhaill, R.E., Oh, D.Y., Johnson, M., Zikaras, K., Smalley, M., Ross, M., Tanyi, J.L., Ghafoor, A., et al. (2023). Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat. Med. 29, 2099-2109. https://doi.org/10.1038/s41591-023-02452-y.
175. Liu, X.F., Onda, M., Schlomer, J., Bassel, L., Kozlov, S., Tai, C.-H., Zhou, Q., Liu, W., Tsao, H.-E., Hassan, R., et al. (2024). Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proc. Natl. Acad. Sci. USA 121, e2317283121. https://doi.org/10.1073/pnas.2317283121.

176. Hugendieck, G., Lettau, M., Andreas, S., Neumann, S., Reinhardt, N., Arnold, P., Theilig, F., Bastian, L., Rogmans, C., Weimer, J.P., et al. (2023). Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer. J. Extracell. Vesicles 12, e12338. https://doi.org/10.1002/jev2.12338.

177. Kyula, J.N., Van Schaeybroeck, S., Doherty, J., Fenning, C.S., Longley, D.B., and Johnston, P.G. (2010). Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 16, 3378-3389. https://doi.org/10.1158/1078-0432.CCR-10-0014.

178. Hassan, R., Remaley, A.T., Sampson, M.L., Zhang, J., Cox, D.D., Pingpank, J., Alexander, R., Willingham, M., Pastan, I., and Onda, M. (2006). Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 12, 447-453. https://doi.org/10.1158/1078-0432.CCR-05-1477.

179. Romero-Ventosa, E.Y., Blanco-Prieto, S., González-Piñeiro, A.L., Rodriguez-Berrocal, F.J., Piñeiro-Corrales, G., and Páez de la Cadena, M. (2015). Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. SpringerPlus 4, 171. https://doi.org/10.1186/s40064-015-0891-0.

180. Asgeirsson, K.S., Agrawal, A., Allen, C., Hitch, A., Ellis, I.O., Chapman, C., Cheung, K.L., and Robertson, J.F.R. (2007). Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer. Breast Cancer Res. 9, R75. https://doi.org/10.1186/bcr1788.

181. Hayashi, H., Chamoto, K., Hatae, R., Kurosaki, T., Togashi, Y., Fukuoka, K., Goto, M., Chiba, Y., Tomida, S., Ota, T., et al. (2024). Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J. Clin. Investig. 134, e168318. https://doi.org/10.1172/JCI168318.

182. Chen, L., Chao, Y., Li, W., Wu, Z., and Wang, Q. (2024). Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications. Biomark. Res. 12, 95. https://doi.org/10.1186/s40364-024-00647-0.

183. Pak, Y., Pastan, I., Kreitman, R.J., and Lee, B. (2014). Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model. PLoS One 9, e110716. https://doi.org/10.1371/journal.pone.0110716.

184. Pak, Y., Zhang, Y., Pastan, I., and Lee, B. (2012). Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 72, 3143-3152. https://doi.org/10.1158/0008-5472.CAN-11-3925.

185. Czerwińska, M., Bilewicz, A., Kruszewski, M., Wegierek-Ciuk, A., and Lankoff, A. (2020). Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives. Molecules 25, 1743. https://doi.org/10.3390/molecules25071743.

186. Chen, X., Sandrine, I.K., Yang, M., Tu, J., and Yuan, X. (2024). MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front. Immunol. 15, 1356913. https://doi.org/10.3389/fimmu.2024.1356913.

187. Kosti, P., Abram-Saliba, J., Pericou-Troquier, L., Pavelot, S., Ruggeri, T., Laffaille, M., Irving, M., Coukos, G., Lanitis, E., and Dunn, S.M. (2025). Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific en-gager. J. Immunother. Cancer 13, e010063. https://doi.org/10.1136/jitc-2024-010063.

188. Wang, X., Ding, Y., Li, S., Wang, F., Yang, L., Zhang, H., and Hong, Z. (2025). Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity. Int. J. Pharm. 669, 125003. https://doi.org/10.1016/j.ijpharm.2024.125003.

189. Reischer, A., Leutbecher, A., Hiller, B., Perini, E., White, K., Hernández-Cáceres, A., Schele, A., Tast, B., Rohrbacher, L., Winter, L., et al. (2025). Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy. Cancer Immunol. Immunother. 74, 214. https://doi.org/10.1007/s00262-025-04032-0.

190. Yue, Y.-L., Liu, J.-J., Ma, H., Pan, Z.d., Wang, L., Zhang, J.-W., Wang, S.-S., Xie, Y.-Q., Jiang, H., Bian, Y.-L., et al. (2025). Generating potent and persistent anti-tumor immunity via affinity-tuned CAR-T cells targeting mesothelin. Acta Pharmacol. Sin. 46, 2849-2862. https://doi.org/10.1038/s41401-025-01572-0.

191. Lu, Z., Shi, M., Zheng, X., Liang, Y., Wang, J., Zou, Z., Luo, R., Feng, M., Yang, X., Zhou, Y., and Li, X. (2024). Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma. Int. J. Pharm. 667, 124946. https://doi.org/10.1016/j.ijpharm.2024.124946.

192. Le, D.T., Wang-Gillam, A., Picozzi, V., Greten, T.F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R.L., et al. (2015). Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33, 1325-1333. https://doi.org/10.1200/JCO.2014.57.4244.

193. Le, D.T., Picozzi, V.J., Ko, A.H., Wainberg, Z.A., Kindler, H., Wang-Gillam, A., Oberstein, P., Morse, M.A., Zeh, H.J., Weekes, C., et al. (2019). Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin. Cancer Res. 25, 5493-5502. https://doi.org/10.1158/1078-0432.CCR-18-2992.

194. Hassan, R., Alley, E.W., Kindler, H.L., Antonia, S.J., Jahan, T.M., Honarmand, S., McDougall, K., Whiting, C.C., Nair, N., Enstrom, A., et al. (2016). CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). J. Clin. Oncol. 34, 8558. https://doi.org/10.1200/JCO.2016.34.15_suppl.8558.

195. Pegna, G.J., Ahmad, M.I., Steinberg, S.M., Peer, C.J., Figg, W.D., FitzGerald, D.J., Hassan, R., Pastan, I., and Alewine, C. (2021). Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors. J. Clin. Oncol. 39, TPS452. https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS452.

196. Chokshi, S., and Hochster, H.S. (2018). An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pre-treated mesothelin-expressing advanced pancreatic cancer. J. Clin. Oncol. 36, TPS540. https://doi.org/10.1200/JCO.2018.36.4_suppl.TPS540.

197. Spiliopoulou, P., Kasi, A., Abushahin, L.I., Cardin, D.B., Lenz, H.-J., Dayyani, F., Messersmith, W.A., Ezenwajiaku, N., Oberstein, P.E., Paluri, R.K., et al. (2022). Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208. J. Clin. Oncol. 40, 4136. https://doi.org/10.1200/JCO.2022.40.16_suppl.4136.

198. Adjei, A.A., Bekaii-Saab, T.S., Berlin, J., Philip, P.A., Mercade, T.M., Walter, A., Cupit, L., Liu, R., Fields, S.Z., and Holynskjy, A. (2018). Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. J. Clin. Oncol. 36, TPS2607. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS2607.

199. Hassan, R., Wang, D., Wrangle, J., Thomas, A., Byars, A., Asschert, L., Atienza, R., Rajagopalan, P., Walter, A., Zhang, J., et al. (2018). Abstract A095: Phase 1b study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer. Mol. Cancer Ther. 17, A095. https://doi.org/10.1158/1535-7163.TARG-17-A095.

200. ter Weele, E.J., Terwisscha van Scheltinga, A.G.T., Kosterink, J.G.W., Pot, L., Vedelaar, S.R., Lamberts, L.E., Williams, S.P., Lub-de Hooge, M.N., and de Vries, E.G.E. (2015). Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget 6, 42081-42090. https://doi.org/10.18632/oncotarget.5877.

201. Roy, J., Jagoda, E.M., Basuli, F., Vasalatiy, O., Phelps, T.E., Wong, K., Ton, A.T., Hagemann, U.B., Cuthbertson, A.S., Cole, P.E., et al. (2021). In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab. Cancer Biother. Radiopharm. 36, 316-325. https://doi.org/10.1089/cbr.2020.4492.

202. Hassan, R., Fennell, D., Scherpereel, A., Nowak, A.K., Von Pawel, J., Novello, S., McLaughlin, M., Hoffman, K., and Wallin, B.A. (2016). A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin
(P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM). J. Clin. Oncol. 34, TPS8577. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS8577.

203. Ko, A.H., Jordan, A.C., Tooker, E., Lacey, S.F., Chang, R.B., Li, Y., Venook, A.P., Tempero, M., Damon, L., Fong, L., et al. (2020). Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol. Ther. 28, 2367-2378. https://doi.org/10.1016/j.ymthe.2020.07.017.

204. Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021). IL-7 and CCL19-secreting CAR-T cell therapy for tumors with pos- itive glypican-3 or mesothelin. J. Hematol. Oncol. 14, 118. https://doi.org/10.1186/s13045-021-01128-9.

205. Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang, X., et al. (2021). Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell. Mol. Immunol. 18, 2188-2198. https://doi.org/10.1038/s41423-021-00749-x.

206. Wang, Z., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Shen, L., Jiang, P., He, J., Ye, X., et al. (2020). Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors. J. Clin. Oncol. 38, 3038. https://doi.org/10.1200/JCO.2020.38.15_suppl.3038.

207. Punekar, S.R., Hecht, J.R., Smith, C.J., Simeone, D.M., Dorigo, O., Boyd, L.R., Kirtane, K., Ward, J., Locke, F.L., Morelli, M.P., et al. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). J. Clin. Oncol. 42, TPS2699. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS2699.

208. Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D., Hu, Y., Zhi, C., et al. (2024). NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. Int. J. Biol. Sci. 20, 1578-1601. https://doi.org/10.7150/ijbs.88539.